Metraipolis › archive › dc_0da34cb60ef7
Preemptive Rituximab for Epstein-Barr Virus Reactivation After Hematopoietic Cell Transplantation: Necessary for All? — Europe PMC PMID:41178384
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41178384
- DOI
- 10.1111/tid.70124
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T19:56:23.383Z
- SHA-256 of the archived text
ae769b4351f804cbc650eb32ad65b33cf5bafc64df143831d54be7cdcd3c2f0c- Stable URL of this page
https://metraipolis.com/documento/dc_0da34cb60ef7
How to cite
Preemptive Rituximab for Epstein-Barr Virus Reactivation After Hematopoietic Cell Transplantation: Necessary for All? — Europe PMC PMID:41178384 — Europe PMC (en), https://europepmc.org/article/MED/41178384 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0da34cb60ef7 (Metraipolis archive dc_0da34cb60ef7, sha256 ae769b4351f804cbc650eb32ad65b33cf5bafc64df143831d54be7cdcd3c2f0c)
BibTeX
@misc{dc0da34cb60ef7,
title = {Preemptive Rituximab for Epstein-Barr Virus Reactivation After Hematopoietic Cell Transplantation: Necessary for All? — Europe PMC PMID:41178384},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41178384},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0da34cb60ef7; sha256 ae769b4351f804cbc650eb32ad65b33cf5bafc64df143831d54be7cdcd3c2f0c},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41178384. Agents can read the archived copy with the MCP tool read_document.